George P Souroullas
Overview
Explore the profile of George P Souroullas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
582
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fowle-Grider R, Rowles 3rd J, Shen I, Wang Y, Schwaiger-Haber M, Dunham A, et al.
Nature
. 2024 Dec;
636(8043):737-744.
PMID: 39633044
Fructose consumption has increased considerably over the past five decades, largely due to the widespread use of high-fructose corn syrup as a sweetener. It has been proposed that fructose promotes...
2.
Zimmerman S, Procasky S, Smith S, Liu J, Torrice C, Souroullas G
bioRxiv
. 2024 Nov;
PMID: 39605688
Mutations in the histone methyltransferase EZH2, particularly the Y641 hotspot mutation, have been implicated in hematologic malignancies, yet the effect of timing and cellular context on their oncogenic potential has...
3.
Zimmerman S, Suh E, Smith S, Souroullas G
Cancer Immunol Immunother
. 2024 Sep;
73(11):218.
PMID: 39235510
Epigenetic modifications to DNA and chromatin control oncogenic and tumor-suppressive mechanisms in melanoma. Ezh2, the catalytic component of the Polycomb Repressive Complex 2 (PRC2), which mediates methylation of lysine 27...
4.
Zimmerman S, Suh E, Smith S, Souroullas G
bioRxiv
. 2024 Jun;
PMID: 38915518
Epigenetic modifications to DNA and chromatin control oncogenic and tumor suppressive mechanisms in melanoma. EZH2, the catalytic component of the Polycomb repressive complex 2 (PRC2), which mediates methylation of lysine...
5.
Paolini R, Souroullas G
Cancer Discov
. 2024 Jun;
14(6):903-905.
PMID: 38826100
In this issue, a study by Kazansky and colleagues explored resistance mechanisms after EZH2 inhibition in malignant rhabdoid tumors (MRT) and epithelioid sarcomas (ES). The study identified genetic alterations in...
6.
Souroullas G, Jeck W, Parker J, Simon J, Liu J, Paulk J, et al.
Nat Med
. 2024 Feb;
30(6):1784.
PMID: 38383796
No abstract available.
7.
Zimmerman S, Lin P, Souroullas G
Front Oncol
. 2023 Sep;
13:1233953.
PMID: 37664059
Mutations in chromatin modifying genes frequently occur in many kinds of cancer. Most mechanistic studies focus on their canonical functions, while therapeutic approaches target their enzymatic activity. Recent studies, however,...
8.
Zimmerman S, Nixon S, Chen P, Raj L, Smith S, Paolini R, et al.
Oncogene
. 2022 Oct;
41(46):4983-4993.
PMID: 36220978
Enhancer of Zeste Homolog 2 (EZH2) is the catalytic component of the Polycomb Repressive Complex 2, a chromatin modifying complex, which mediates methylation of lysine 27 on histone 3 (H3K27me3),...
9.
Goldsmith S, Fiala M, ONeal J, Souroullas G, Toama W, Vij R, et al.
Clin Lymphoma Myeloma Leuk
. 2019 Sep;
19(11):744-750.
PMID: 31551170
Background: EZH2 is a histone methyltransferase that suppresses genes involved in cell cycle control. Overexpression of EZH2 has been associated with a poor prognosis in various malignancies. Pawlyn et al...
10.
Liu J, Souroullas G, Diekman B, Krishnamurthy J, Hall B, Sorrentino J, et al.
Proc Natl Acad Sci U S A
. 2019 Jan;
116(7):2603-2611.
PMID: 30683717
The activation of cellular senescence throughout the lifespan promotes tumor suppression, whereas the persistence of senescent cells contributes to aspects of aging. This theory has been limited, however, by an...